Granisetron HCl 1 mg/ML Injectable Solution
RxNorm 240912
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 240912 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: granisetron HCl 1 mg/ML Injectable Solution.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Granisetron 1 mg/ML Injectable Solution
(Atom ID: 12336973)
PTPrescribable
Designated preferred name (PT):
Granisetron (as granisetron hydrochloride) 1 mg/mL solution for injection
(Atom ID: 10803890)
SYPrescribable
Synonym (SY):
Granisetron 1 mg (as granisetron HCl 1.12 mg) per mL Injectable Solution
(Atom ID: 7737121)
PSNPrescribable
Prescribable Name (PSN):
Granisetron HCl 1 mg/ML Injectable Solution
(Atom ID: 7728777)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely granisetron (as granisetron hydrochloride) 1 mg/1 mL conventional release solution for injection (clinical drug)
(Atom ID: 10818873)
Patient Education
Granisetron Injection
Granisetron immediate-release injection is used to prevent nausea and vomiting caused by cancer chemotherapy and to prevent and treat nausea and vomiting that may occur after surgery. Granisetron extended-release (long-acting) injection is used with other medications to prevent nausea and vomiting caused by cancer chemotherapy that may occur immediately or several days after receiving chemotherapy medications. Granisetron is in a class of medications called 5-HT3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting.
[Learn More]
* Please review the disclaimer below.